Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study

Hormazábal, Juan; Nuñez-Franz, Loreto; Rubilar, Paola; Apablaza, Mauricio; Vial, Cecilia; Cortés, Lina Jimena; González, Natalia; Vial, Pablo; Said, Macarena; González, Claudia; Olivares, Kathya; Aguilera, Ximena; Ramírez-Santana, Muriel

doi:10.1016/j.jvacx.2023.100372

Vaccine: X

2023

DOI: 10.1016/j.jvacx.2023.100372

|View full text |Cite

Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study

Juan Hormazábal,

Loreto Nuñez-Franz,

Paola Rubilar

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients

Gallardo-Nelson,

Cruces,

Gómez

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Objectiveto evaluate the immune response to the SARS-CoV-2 vaccines in adults with immune-mediated rheumatic diseases (IMRDs) in comparison to healthy individuals, observed 1-20 weeks following the fourth vaccine dose. Additionally, to evaluate the impact of immunosuppressive therapies, vaccination schedules, the time interval between vaccination and sample collection on the vaccine’s immune response.MethodsWe designed a longitudinal observational study conducted at the rheumatology department of Hospital de Copiapó. Neutralizing antibodies (Nabs) titers against the Wuhan and Omicron variant were analyzed between 1-20 weeks after administration of the fourth dose of the SARS-CoV-2 vaccine to 341 participants (218 IMRD patients and 123 healthy controls). 218 IMRD patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), systemic vasculitis (VS) and systemic scleroderma (SS) were analyzed.ResultsPerforming a comparison between the variants, Wuhan vs Omicron, we noticed that there were significant differences (p<0.05) in the level of the ID50, both for healthy controls and for patients with IMRDs. The humoral response of patients with IMRDs is significantly lower compared to healthy controls for the Omicron variant of SARS-CoV-2 (p = 0.0015). The humoral response of patients with IMRDs decreases significantly when the time interval between vaccination and sample collection is greater than 35 days. This difference was observed in the response, both for the Wuhan variant and for the Omicron variant.ConclusionThe IMRDs patients, the humoral response variation in the SARS-CoV-2 vaccine depends on doses and type of vaccine administered, the humoral response times and the treatment that these patients are receiving.

show abstract

4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients

Gallardo-Nelson,

Cruces,

Gómez

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study

Cited by 1 publication

References 26 publications

4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients

4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients

Contact Info

Product

Resources

About